CRISPR Therapeutics CRSP Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.46M+68.8% | $864K-2.8% | $889K-0.3% | $892K+3.1% | $865K-97.6% | ||
| $68.57M-17.9% | $83.53M+41.8% | $58.9M-15.7% | $69.89M-3.6% | $72.48M+1.0% | ||
| $17.18M-6.6% | $18.4M+8.7% | $16.93M-10.5% | $18.92M-2.0% | $19.3M+6.5% | ||
| $131.71M-15.4% | $155.63M+17.1% | $132.95M-42.3% | $230.22M+54.2% | $149.29M+48.9% | ||
| -$130.25M+15.8% | -$154.76M-17.2% | -$132.06M+42.4% | -$229.32M-54.5% | -$148.42M-130% | ||
| -8,933.3%+8,979pp | -17,912.5%-3,058pp | -14,854.8%+10,854pp | -25,709%-8,550pp | -17,158.8%-16,978pp | ||
| $8.16M-67.1% | $24.77M-5.6% | $26.24M+18.9% | $22.07M+63.0% | $13.54M-51.6% | ||
| -$122.09M+6.1% | -$130M-22.8% | -$105.82M+48.9% | -$207.26M-53.7% | -$134.89M-268% | ||
| $839K+36.6% | $614K-0.8% | $619K-52.1% | $1.29M+16.5% | $1.11M+58.4% | ||
| -$122.93M+5.9% | -$130.61M-22.7% | -$106.44M+49.0% | -$208.55M-53.3% | -$136M-264% | ||
| -8,431.5%+6,686pp | -15,117.2%-3,144pp | -11,973.1%+11,407pp | -23,379.9%-7,658pp | -15,722.1%-15,618pp | ||
| -$1.28+5.2% | -$1.35-15.4% | -$1.17+51.3% | -$2.40-51.9% | -$1.58-276% | ||
| -$125.93M+15.5% | -$149.1M-16.8% | -$127.63M+43.2% | -$224.68M-56.4% | -$143.69M-140% | ||
| -8,637.1%+8,620pp | -17,257.3%-2,901pp | -14,356.1%+10,832pp | -25,187.8%-8,576pp | -16,611.3%-16,444pp | ||
| -$130.25M+15.8% | -$154.76M-17.2% | -$132.06M+42.4% | -$229.32M-54.5% | -$148.42M-130% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does CRISPR Therapeutics's income statement data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.